Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
- R. Pauwels, C. Löfdahl, A. Ullman
- MedicineNew England Journal of Medicine
- 13 November 1997
In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonid therapy or the use of a higher dose of budesonide may be beneficial.
Health-related quality of life is related to COPD disease severity
- E. Ståhl, A. Lindberg, B. Lundbäck
- Medicine, PsychologyHealth and Quality of Life Outcomes
- 9 September 2005
The results show that HRQL in COPD deteriorates with disease severity and with age, and a relationship between HRQL and disease severity obtained by lung function is shown.
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary…
- R. Pauwels, C. Löfdahl, S. Ohlsson
- MedicineNew England Journal of Medicine
- 1999
In patients with mild COPD who continue smoking, the use of inhaled budesonide is associated with a small one-time improvement in lung function but does not appreciably affect the long-term progressive decline.
Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study.
- R. Kessler, E. Ståhl, M. Partridge
- Medicine, PsychologyChest
- 1 July 2006
Patient recollections suggest that exacerbation profiles vary enormously between patients but that symptoms/warning signs are fairly consistent within individuals, and are generally recognizable.
COPD exacerbations: the importance of a standard definition.
- R. Pauwels, P. Calverley, C. Löfdahl
- MedicineRespiratory Medicine
- 1 February 2004
Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking
- R. Pauwels, C. Löfdahl, S. Ohlsson
- Medicine
- 24 June 1999
A double-blind, placebo-controlled study evaluated the effect of the inhaled glucocorticoid budesonide in subjects with mild COPD who continued smoking and found that the FEV1 improved at the rate of 17 ml per year in the budesonid group, which was higher than the predicted value.
Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study
- M. Miravitlles, H. Worth, A. Ribera
- Medicine, PsychologyRespiratory Research
- 21 October 2014
Night-time, early morning and daytime COPD symptoms were all associated with worse dyspnoea, health status and sleep quality, and higher anxiety and depression levels, suggesting that improving 24-hour symptoms should be an important consideration in the management of COPD.
Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD
- C. Löfdahl, D. Postma, N. Pride, J. Boe, A. Thorén
- MedicineEuropean Respiratory Journal
- 1 June 2007
The hypothesis that treatment with inhaled budesonide reduces ischaemic cardiac events in patients with mild chronic obstructive pulmonary disease is supported.
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.
- A. Tattersfield, D. Postma, A. Ullman
- MedicineAmerican Journal of Respiratory and Critical Care…
- 1 August 1999
Exacerbations identified by the need for oral corticosteroids were associated with more symptoms and smaller changes in PEF than those identified on the basis of PEF criteria, and female sex was the main patient characteristic associated with an increased risk of having a severe exacerbation.
Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis.
- G. Riise, S. Larsson, C. Löfdahl, B. Andersson
- Medicine, BiologyEuropean Respiratory Journal
- 1 September 1994
The results indicate that cCAMs may reflect an upregulation of CAMs on endothelial and epithelial airway cells in COPD.
...
...